TREATMENT OF FALSE-NEGATIVE METASTATIC LYMPH NODES BY A LYMPHATIC DRUG DELIVERY SYSTEM WITH 5-FLUOROURACIL

Honoka Fujii1,2 | Sachiko Horie1,2 | Ariunbuyan Sukhbaatar1,2,3 | Radhika Mishra1,4 | Maya Sakamoto5 | Shiro Mori1,2,6 | Tetsuya Kodama1,2 *

INTRODUCTION

Lymph node (LN) metastasis in patients with cancer is considered to be an important predictor of poor prognosis. There has been much debate about how tumor cells spread to distant organs hematogenously via LNs.1–4 Recently, several papers have reported that metastatic LNs could be the origin of systemic metastases.5–7 Brown et al.5 determined that high...
endothelial venules play an important role in hematogenous metastasis, and Pereira et al.\textsuperscript{7} concluded that tumor cells invade local vessels in LNs and that this is followed by hematogenous metastasis. Kodama et al.\textsuperscript{8} demonstrated that the initiation of hematogenous metastasis is tumor cell invasion from the marginal sinus of a LN into the extranodal veins, and the authors advocated the theory of LN-mediated hematogenous metastasis.\textsuperscript{6,8,9} Several clinical trials have indicated that surgical excision of tumor-draining LNs has no effect on the long-term survival of patients with cancer.\textsuperscript{10-12} These findings suggest that tumor cells are seeded throughout the body at the stage where micrometastasis exists in the LNs, and as a result, surgical dissection does not affect the long-term survival of cancer patients; this result would support the validity of the LN-mediated hematogenous metastasis theory.

Although the theory of LN-mediated hematogenous metastasis needs confirmation in a clinical setting, it is clear that a new strategy is required that prevents systemic metastasis by treating metastatic LNs at the early stage of metastasis. Since LNs have a rich vascular network,\textsuperscript{13} tumor cells can develop in them without tumor angiogenesis.\textsuperscript{14,15} Thus, hematogenous delivery of macromolecular drugs based on the enhanced permeability and retention effect\textsuperscript{16} and normalization of the circulation (ie, improvement of the flow and functions of the vasculature)\textsuperscript{17} would not be effective in the treatment of metastatic LNs. In addition, the lymphatic system preferentially takes up large-sized particles and high molecular weight substances. Particles 10-100 nm in size are reabsorbed from the interstitial space by the lymphatic system,\textsuperscript{18,19} while those < 10 nm in size are primarily reabsorbed by blood vessels. The efficiency of reabsorption into the lymphatic system correlates positively with molecular weight, and substances with a molecular weight above 16 000 g/mol are mainly taken up by the lymphatic system.\textsuperscript{20,21} Since anticancer drugs are usually small molecules, generally they are poorly delivered to the lymphatic system after systemic administration.

For the above reasons, the use of a LDDS to deliver anticancer drugs efficiently to false-negative metastatic LNs during the early stage of metastasis has been proposed.\textsuperscript{22} False-negative metastatic LNs are those that contain tumor cells but, due to the early stage of tumor development, have a size and shape similar to those of LNs not hosting tumor cells. The LDDS is a new approach to treat or prevent LN micrometastasis, and we have previously demonstrated this novel therapeutic concept.\textsuperscript{23} The LDDS operates by injecting drugs into sentinel (upstream) LNs in order to deliver them to downstream metastatic LNs in the lymphatic network and maintain high concentrations of drug within the targeted LNs.

The aim of this investigation was to examine the therapeutic effects of 5-FU administered through a LDDS on false-negative metastatic LNs. 5-Fluorouracil has been widely used to treat LN metastasis in breast and gastric cancer. First, the antitumor effects of 5-FU were assessed in four different cell lines using in vivo cytotoxicity and cell survival assays. Next, mouse models of LN metastasis (generated using two tumor cell lines with different growth characteristics) were utilized to evaluate the therapeutic effects of LDDS-administered 5-FU on false-negative metastatic LNs. It was found that by using a LDDS, the administration of 5-FU is an effective treatment for LNs with false-negative metastases.

2 | METHODS

The Tohoku University Institutional Animal Care and Use Committee approved the in vivo study protocols.

2.1 | Culture of cells

Cultured cells used in the experiments were MRL/ MpTn-gld/gld mouse malignant KM-Luc/GFP cells that stably expressed a fusion of the enhanced-green fluorescent protein and luciferase genes were maintained in culture,\textsuperscript{24} as were BALB/cCrI mouse mammary carcinoma cells (EMT6-Luc) that stably expressed the firefly luciferase gene,\textsuperscript{25} C3H/He mouse Dunn osteosarcoma cells (LM8-Luc) stably expressing the firefly luciferase gene,\textsuperscript{26} and C3H/He mouse mammary carcinoma cells (FM3A-Luc) stably expressing the Luc gene.\textsuperscript{27} KM-Luc/GFP, EMT6-Luc and LM8 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St Louis, MO) supplemented with 10% heat-inactivated fetal bovine serum (FBS; HyClone Laboratories Inc., UT, US) and 1% l-glutamine–penicillin–streptomycin (Sigma-Aldrich). FM3A-Luc cells were maintained in RPMI-1640 medium supplemented with 10% (v/v) FBS (HyClone Laboratories Inc.), 1% (v/v) l-glutamine–penicillin–streptomycin and 1 mg/mL G418 (Wako Pure Chemical Industries, Osaka, Japan). Cell lines were incubated at 37°C in an atmosphere of 5% CO\textsubscript{2} and 95% air until 80% confluence was achieved. A lack of Mycoplasma contamination was confirmed for all in vivo experiments on the inoculation day using a MycoAlert Mycoplasma Detection Kit (Lonza Rockland, ME, US).

2.2 | In vitro cytotoxicity and cell survival assays

The cytotoxic effects of 5-FU on KM-Luc/GFP cells (n = 8) and FM3A-Luc cells (n = 8) in 96-well plates were measured using a lactate dehydrogenase (LDH) assay according to the protocol provided by the kit manufacturer (LDH-cytotoxicity kit; Wako Pure Chemical Industries). The cytotoxicity ratio was calculated thus:

\[
\text{Cytotoxicity ratio (\%) = } \frac{S - N}{P - N} \times 100
\]
where $S$ is the mean absorbance of the wells to which 5-FU was added, $N$ the average absorbance of negative control wells, and $P$ the average absorbance of positive control wells. The MTT assay was carried out for KM-Luc/GFP ($n = 12$), FM3A-Luc ($n = 12$), EMT6-Luc ($n = 7$), and LM8-Luc ($n = 8$) cells in 96-well plates, as previously described. The cell survival ratio was determined by the following equation:

$$\text{Cell survival ratio} (\%) = \frac{A_x}{A_0} \times 100 \quad (2)$$

where $A_x$ is the average absorbance of the wells to which 5-FU was added and $A_0$ the average absorbance of the wells without 5-FU.

### 2.3 Mice

MHX10/Mo-lpr/lpr (MXH10/Mo/lpr) mice (aged 16-18 weeks) were bred under specific pathogen-free conditions in the Animal Research Institute, Tohoku University. MHX10/Mo/lpr mice are exceptional in that their peripheral LNs develop to 10 mm in size at 2.5 to 3 months, and they do not exhibit autoimmune disease. In the present study, we used the term “subiliac LN” instead of “inguinal LN” to assign the correct anatomical locations and nomenclatures to murine LNs.

### 2.4 Induction of metastasis in the proper axillary LN (PALN) by injection of tumor cells into the subiliac LN (SiLN)

Mice were anesthetized (2% isoflurane in O$_2$), and the unilateral SiLN injected (under US guidance) with KM-Luc/GFP cells ($3 \times 10^5$ cells/mL) or FM3A-Luc cells ($3 \times 10^6$ cells/mL) suspended in 10 μL phosphate-buffered saline plus 20 μL of 400 mg/mL Matrigel (Collaborative Biomedical Products, Bedford, MA). Tumor cells were injected into the SiLN to induce metastasis in the PALN. The day of tumor cell inoculation was defined as day 0. Tumor growth in the PALN was assessed with an in vivo bioluminescence imaging system (IVIS; PerkinElmer, Waltham, MA) under the guidance of a high-frequency ultrasound imaging system (VEVO770; VisualSonics, Toronto, Canada) with a 25-MHz transducer (RMV-710B; axial resolution, 70 μm; focal length, 15 mm; VisualSonics) on day 0T.

### 2.5 Treatment of the metastatic PALN with 5-FU

Mice with confirmed metastasis of KM-Luc/GFP cells to the PALN were randomly divided into four groups based on the concentration of 5-FU administered: control (saline alone, ie, 0 μg/g; $n = 4$), 0.1 μg/g ($n = 4$), 1 μg/g ($n = 4$), and 10 μg/g ($n = 4$). Mice with confirmed metastasis of FM3A-Luc cells to the PALN were randomly divided into five groups thus: control (saline alone, ie, 0 μg/g; $n = 6$), 0.1 μg/g ($n = 5$), 1 μg/g ($n = 5$), 10 μg/g ($n = 5$), and 100 μg/g ($n = 5$). Each mouse was deeply anesthetized with 2% isoflurane (Abbott Japan, Chiba, Japan) in O$_2$, and 120 μL of the appropriate solution was injected into the accessory axillary LN (AALN). Injection of 5-FU solution into the AALN was carried out with a 27-G butterfly needle at an injection speed of 10 μL/min using a syringe pump (Legato100; KD Scientific, Holliston, MA, US) under the guidance of a high-frequency ultrasound imaging system (VEVO770; VisualSonics) with a 25-MHz transducer (RMV-710B; axial resolution, 70 μm; focal length, 15 mm; VisualSonics) on day 0T.

### 2.6 Measurement of SiLN and PALN volumes

SiLN and PALN volumes were measured using a high-frequency ultrasound imaging system (VEVO770; VisualSonics) with a 25-MHz transducer (RMV-710B; VisualSonics) on day 3 (ie, -6T), day 6 (ie, 0T), and day 9 (ie, 3T) for KM-Luc/GFP cells and on day 0, day 0T, and day 9T for FM3A-Luc cells.

### 2.7 Ex vivo measurement of tumor growth

The PALN was harvested on day 3T for KM-Luc/GFP cells and on day 9T for FM3A-Luc cells. Luciferase activity in the samples (in six-well plates) was measured with the IVIS (0.3 mg/mL luciferin). Luciferase activity was evaluated on both sides of each sample to obtain the average luciferase activity.

### 2.8 Blood biochemistry to assess renal/hepatic toxicity of 5-FU

Mice were assigned into five groups based on the tumor cell line and 5-FU concentration used thus: KM-Luc/GFP, 0 μg/g ($n = 4$); KM-Luc/GFP, 10 μg/g ($n = 4$); FM3A-Luc, 0 μg/g ($n = 6$); FM3A-Luc, 10 μg/g ($n = 5$); and FM3A-Luc, 100 μg/g ($n = 5$). Blood was drawn from the left ventricle on day 3T (KM-Luc/GFP) or day 9T (FM3A-Luc), and plasma was obtained by centrifugation at 13 000 g for 10 seconds. Hepatic and renal functions were evaluated from plasma measurements of total bilirubin (T-BIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cre), and blood urea nitrogen (BUN) (Oriental Yeast, Tokyo, Japan).
2.9 | Weight measurement

To evaluate any acute toxic effects of 5-FU, the body weights of mice were measured and recorded. For mice inoculated with KM-Luc/GFP cells, body weights were measured on days 0, 3, 6 (0T), and 9 (3T). For mice inoculated with FM3A-Luc cells, body weights were measured on days 0, -1T, 0T, 3T, 6T, and 9T. 

2.10 | Histological analysis

Tissues (PALN, AALN, lung, liver, and kidney) were excised on day 3T (KM-Luc/GFP) or day 9T (FM3A-Luc), fixed overnight in 10% formalin at 4°C, dehydrated, embedded in paraffin, serially sectioned (3-4 μm), and either stained with hematoxylin and eosin (H&E) or immunostained for LYVE-1-positive and CD31-positive cells (Discovery XT Automated Staining Processor; Ventana Medical Systems, Tucson, AZ).30

2.11 | Statistical analysis

All data are expressed as the mean ± standard error of the mean (SEM) or the mean ± standard deviation (SD).

Statistical analysis was performed using a one-way repeated-measures ANOVA, two-way repeated-measures ANOVA, Kruskal-Wallis test, Tukey test, or an unpaired t-test as appropriate. A value of P < 0.05 was considered to be a statistically significant difference.

3 | RESULTS

3.1 | In vitro cytotoxicity assay

The measurement of the cell survival ratio by the MTT assay demonstrated that 5-FU caused a concentration-dependent decrease in viability of all tumor cell lines (Figure 1A). For KM-Luc/GFP cells, a statistically significant decrease in cell viability was observed
at 1 μmol/L, 10 μmol/L, 100 μmol/L, and 1000 μmol/L. 5-FU (P < 0.001, 10 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; P < 0.05, 1 μmol/L vs 0 μmol/L; one-way ANOVA and Dunnett’s test). For FM3A-Luc cells, statistically significant decreases in the cell survival ratio were observed at all concentrations of 5-FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 10 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L and 1000 μmol/L vs 0 μmol/L; P < 0.05, 0.1 μmol/L vs 0 μmol/L; one-way ANOVA and Dunnett’s test). In EMT6-Luc cells, 5-FU concentrations of 1 μmol/L, 10 μmol/L, 100 μmol/L, and 1000 μmol/L elicited statistically significant decreases in cell viability (P < 0.001, 1000 μmol/L vs 0 μmol/L; P < 0.01, 10 μmol/L vs 0 μmol/L and 100 μmol/L vs 0 μmol/L; P < 0.05, 1 μmol/L vs 0 μmol/L). In LM8-Luc cells, statistically significant decreases in cell viability were observed at 1 μmol/L, 10 μmol/L, 100 μmol/L, and 1000 μmol/L. 5-FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 10 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L).

Since KM-Luc/GFP and FM3A-Luc cells have been confirmed to engraft in mice in previous research, these two cell lines were chosen for further experiments. The LDH assay revealed that 5-FU exerted only minor cytotoxic effects on KM-Luc/GFP and FM3A-Luc cells (Figure 1B). For KM-Luc/GFP cells, a statistically significant increase in the cytotoxicity ratio was observed for 1000 μmol/L 5-FU (P < 0.001, 1000 μmol/L vs 0 μmol/L; one-way ANOVA and Dunnett’s test). In FM3A-Luc cells, a statistically significant increase in the cytotoxicity ratio was observed for 1 μmol/L, 10 μmol/L, and 1000 μmol/L. 5-FU (P < 0.001, 1 μmol/L vs 0 μmol/L, 100 μmol/L vs 0 μmol/L, and 1000 μmol/L vs 0 μmol/L; one-way ANOVA and Dunnett’s test).

3.2 Measurements of PALN volume before and after the occurrence of metastasis

To confirm that the present animal model was suitable for the study of false-negative metastatic LNs, a high-frequency ultrasound imaging system was used to compare PALN volumes before (day 0) and after (day 0T) the induction of metastasis. Figure 2A shows that there was no significant increase in PALN volume between day 0 (6T, n = 13) and day 0T (n = 13) when KM-Luc/GFP cells were used to induce metastasis. As shown in Figure 2B, PALN volume decreased significantly between day 0 (n = 26) and day 0T (n = 26) when FM3A-Luc cells were used to induce metastasis (P < 0.05, day 0 vs day 0T; paired t test). The absence of an increase in PALN volume after the induction of metastasis with KM-Luc/GFP or FM3A-Luc cells confirmed that, in both cases, the PALN was a false-negative metastatic LN.

3.3 Treatment of a false-negative metastatic LN using 5-FU administered by a LDDS

Luciferase activity was measured to evaluate tumor size before and after the administration of 5-FU with a LDDS. Luciferase activity was determined on days –3T, 0T, and 3T for KM-Luc/GFP cells (Figure 3A) and days –1T, 3T, 6T, and 9T for FM3A-Luc cells (Figure 3C). Figure 3B shows the luciferase activity of KM-Luc/GFP cells on day 3T normalized to that on day 0T (NS: not significant; paired t test). There was no significant reduction in luciferase activity for any of the 5-FU concentrations tested (Figure 3D). When KM-Luc/GFP cells were used, there were no significant reductions in luciferase activity after the delivery of 10 μg/g 5-FU, although statistical significance was not attained (Figure 3B). When FM3A-Luc cells were used, there were no significant differences in luciferase activity for any of the 5-FU concentrations tested (Figure 3D).
3.4 | Changes in the volumes of the PALN and AALN after 5-FU administration with a LDDS

Changes in AALN and PALN volumes (assessed using a high-frequency ultrasound imaging system) were used to evaluate the antitumor effect of 5-FU. Figure 4A-D show results for experiments using KM-Luc/GFP cells. Figure 4A and B show representative images of the AALN and PALN on day 0 of 5-FU concentrations of 0 μg/g (control) and 10 μg/g. Figure 4C and D show AALN and PALN volumes normalized to the volume on day 0. There were no significant differences in AALN volumes between groups (Figure 4D). There were no significant differences in the PALN volume between groups (Figure 4H).

3.5 | Ex vivo assessment of the antitumor effect of 5-FU

Figure 5 shows representative ex vivo bioluminescence images of the PALN for each group (ie, each 5-FU concentration). In vivo bioluminescence intensity was measured on...
day 3\textsuperscript{T} for KM-Luc/GFP cells and day 9\textsuperscript{T} for FM3A-Luc cells. The PALN was then excised to permit measurements of ex vivo bioluminescence intensity. There were no significant differences in ex vivo bioluminescence intensity between the control group and each 5-FU group for both KM-Luc/GFP cells (Figure 5A and B; one-way ANOVA and Kruskal-Wallis test) and FM3A-Luc cells (Figure 5C and D; one-way ANOVA and Kruskal-Wallis test).

### 3.6 Blood biochemistry and animal weight

To determine whether the use of the LDDS was associated with toxicity, blood biochemical parameters on day 3\textsuperscript{T} (KM-Luc/GFP cells) and day 9\textsuperscript{T} (FM3A-Luc cells), and changes in animal weight during the study were assessed. There were no significant changes in biochemical parameters or body weight for both cell lines (Table 1).

### 3.7 Histological analysis of the PALN

Figure 6 shows histological analysis of the PALN after the administration of 5-FU with the LDDS. In experiments using KM-Luc/GFP cells, tumor cells were detected in and near the marginal sinus in the control group (Figure 6A-C), with tumor cells located near the lymphatic sinus and blood vessels (arrows in Figure 6B and C). In the 10 μg/g 5-FU group,
tumor-containing regions were not detected (Figure 6D–F). In experiments utilizing FM3A-Luc cells, a tumor-containing region was detected in the lymphatic sinus (Figure 6H and K) but not blood vessels (Figure 6I and L) in both the groups.

4 | DISCUSSION

Lymph node metastasis occurs in many carcinomas, and its treatment improves the prognosis of patients. Lymph node metastasis has been thought to result from tumor cells breaking off from the primary tumor to enter the lymphatic vessels and pass through a series of LNs before reaching the thoracic duct and subclavian vein.\textsuperscript{31} Recently, the theory of LN-mediated hematogenous metastasis was advocated,\textsuperscript{6,9} suggesting that tumor cell invasion from the marginal sinus into extranodal veins during early stage LN metastasis could be the starting point for hematogenous metastasis.\textsuperscript{6} In other words, systemic metastasis could potentially be prevented by treating false-negative metastatic LNs. Furthermore, there is evidence that dormant cancer cells may be activated by surgical dissection of LNs in patients\textsuperscript{32,33} and in a mouse model.\textsuperscript{34-36} These findings question whether conventional LN dissection contributes substantially to an improvement in the prognosis of patients.

The present study first explored the cytotoxic effects of 5-FU in vitro and then evaluated the therapeutic effects of 5-FU administered by a LDDS in a mouse model of a false-negative metastatic LN, which was developed using two different tumor cell lines (KM-Luc/GFP and FM3A-Luc cells). In vitro experiments revealed that four different cell lines were sensitive to increasing concentrations of 5-FU (Figure 1). In

FIGURE 5 Ex vivo assessment of the antitumor effect of 5-fluorouracil (5-FU). A, B: KM-Luc/GFP cells. C, D: FM3A-Luc cells. A, C: Representative ex vivo bioluminescence images of the proper axillary lymph node (PALN) for each group (ie, each concentration of 5-FU) on day 3\textsuperscript{T} for KM-Luc/GFP cells (A) and day 9\textsuperscript{T} for FM3A-Luc cells (C). B, D: Ex vivo bioluminescence intensity for KM-Luc/GFP cells (B) and FM3A-Luc cells (D). There were no significant differences in ex vivo bioluminescence intensity between the control group and each 5-FU group for both KM-Luc/GFP cells and FM3A-Luc cells (NS: not significant; one-way ANOVA and Kruskal-Wallis test). Data are presented as the mean ± SEM (0 μg/g, n = 6; 0.1 μg/g, n = 5; 1 μg/g, n = 5; 10 μg/g, n = 5; 100 μg/g, n = 5).
**Table 1** Evaluation of the acute toxicity of 5-FU

|                | KM-Luc/GFP | Statistical significance | FM3A-Luc | Statistical significance |
|----------------|------------|--------------------------|----------|--------------------------|
|                | 0 μg/g (n = 4) | 10 μg/g (n = 4) | 0 μg/g (n = 6) | 10 μg/g (n = 5) | 100 μg/g (n = 5) |
| CRE (mg/dL)    | 0.10 ± 0.01 | 0.10 ± 0.01 | NS | 0.08 ± 0.02 | 0.09 ± 0.01 | 0.09 ± 0.02 | NS |
| BUN (mg/dL)    | 26.6 ± 3.4  | 34.4 ± 15.9 | NS | 34.1 ± 10.3 | 32.8 ± 9.7 | 32.5 ± 5.3 | NS |
| T-BIL (IU/L)   | 0.04 ± 0.03 | 0.02 ± 0.01 | NS | 0.04 ± 0.03 | 0.13 ± 0.18 | 0.03 ± 0.02 | NS |
| AMY (IU/L)     | 2001.0 ± 88.3 | 2275 ± 741.8 | NS | 2115.3 ± 391.8 | 2302.4 ± 647.5 | 2117.2 ± 180.0 | NS |
| ALT (IU/L)     | 37.5 ± 6.2  | 44.3 ± 12.0 | NS | 51.0 ± 15.1 | 66.8 ± 43.1 | 35.2 ± 6.5 | NS |
| AST (IU/L)     | 127.0 ± 32.3 | 115.3 ± 19.1 | NS | 144.2 ± 37.1 | 157.8 ± 66.2 | 122.2 ± 21.8 | NS |
| Weight change (g) | −1.00 ± 1.22 | −0.25 ± 0.43 | NS | −1.00 ± 2.94 | 1.60 ± 1.36 | 0.40 ± 0.80 | NS |

Samples were obtained on day 3	extsuperscript{T} for KM-Luc/GFP cells and on day 9	extsuperscript{T} for FM3A-Luc cells. CRE, creatinine; BUN, blood urea nitrogen; T-BIL, total bilirubin; AMY, amylase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NS, not significant.

	extsuperscript{a}Values are mean ± SEM.

	extsuperscript{b}Unpaired t test.

	extsuperscript{c}Kruskal-Wallis test.

**Figure 6** Histological analysis of the proper axillary lymph node (PALN).

A-F: KM-Luc/GFP cells. In the control group (A-C), tumor cells were detected in and near the marginal sinus and in the vicinity of the lymphatic sinus (arrows) and blood vessels (arrow heads). In the 10 μg/g 5-fluorouracil (5-FU) group (D-F), a region containing tumor cells was not detected.

G-L: FM3A-Luc cells. In both the control group (G-I) and 10 μg/g 5-FU group (J-L), tumor was detected in the lymphatic sinus (H, K) but not in blood vessels (I, L). A, D, G, J: HE staining. B, E, H, K: anti-LYVE-1 staining. C, F, I, L: anti-CD31 staining. T: tumor. Scale bar: 100 μm

Vivo experiments in MXH10/Mo/lpr mice demonstrated a significant antitumor effect of 5-FU against KM-Luc/GFP cells but not FM3A-Luc cells (Figures 3-6). This discrepancy may reflect differences in the invasion patterns of the two cell types. KM-Luc/GFP cells have low invasive growth characteristics and form tumor regions with well-defined borders.
in or near the marginal sinuses (Figs 6A-D). On the other hand, FM3A-Luc cells have high invasive growth characteristics, proliferate along the trabecular sinus, and invade the cortex and paracortex (Figs 6I-P). Drugs delivered from the AALN to the PALN likely reached KM-Luc/GFP cells proliferating in the marginal sinus but not FM3A-Luc cells invading the trabecular sinus and cortex. Under normal physiological conditions, about 90% of lymph flows into a peripheral path via the marginal and medullary sinuses, that is, drugs in the marginal and medullary sinuses are washed out by lymph.

For this reason, a LDDS needs to deliver drugs into the medulla of a metastatic LN. Although physicochemical properties such as particle size, composition, dose, surface charge, and molecular weight are considered to be important factors determining the in vivo behavior of particulates, another factor facilitating the delivery of a drug to a downstream LN is the rate of drug injection into an upstream LN. We found that intranodal injection of a drug into an upstream LN at a rate < 100 μL/min allowed downstream LNs to accumulate the drug and this efficacy was explained by the impulse values calculated from injection pressures in the upstream LN.

The present study used MXH10/Mo/lpr mice, which show systemic lymphadenopathy from 8 weeks of age due to the accumulation of lpr-T cells. MXH10/Mo/lpr mice do not express the fas gene involved in apoptosis, since the lpr gene is a fas-deletion mutant gene. Thus, the immune system in MXH10/Mo/lpr mice is functional except for the signaling pathway related to fas. Most previous studies of LN metastasis have used experimental systems based on human xenografts formed in immunocompromised mice. Given the relevance of immune function to LN metastasis, we consider MHX10/Mo/lpr mice to be a superior model system to immunocompromised mice.

The present study examined the effects of 5-FU, which inhibits DNA synthesis by restricting the availability of thymidylate during the S phase of the cell cycle. Our previous investigations utilized cisplatin, a platinum-containing compound belonging to the alkylating agent family, and doxorubicin, which inhibits the progression of an enzyme (topoisomerase II) that relaxes DNA supercoils involved in transcription. Both cisplatin and doxorubicin were effective in the treatment of metastatic LNs when administered using a LDDS, indicating that conventional drugs used in the clinic have the potential to treat metastatic LNs when administered with this novel approach. A potential important advantage of a LDDS over systemic chemotherapy is that treatment of a metastatic LN requires much smaller quantities of drug (1/100 to 1/10 000 of the amount), which would minimize side effects due to drug administration (Table 1). This finding strongly indicates that drug administration with a LDDS would likely not be associated with serious adverse events. We anticipate that the effectiveness of drug administration with a LDDS in the treatment and prevention of false-negative metastatic LNs will be evaluated further in future clinical trials.

ACKNOWLEDGMENTS

This study was supported in part by JSPS KAKENHI grant numbers 18H03544 (Maya Sakamoto), 17K20077 (Tetsuya Kodama), and 17H00865 (Tetsuya Kodama). The authors thank T. Sato for technical assistance and the Biomedical Research Core of Tohoku University Graduate School of Medicine for technical support.

CONFLICTS OF INTEREST

Tetsuya Kodama received commercial research support from Yakult Honsha Co., Ltd. The other authors declare no conflicts of interest.

ORCID

Tetsuya Kodama https://orcid.org/0000-0003-4727-9558

REFERENCES

1. Fisher B, Fisher ER. Transmigration of lymph nodes by tumor cells. Science. 1966;152:1397-1398.
2. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994;12:2229-2234.
3. Cady B. Regional lymph node metastases, a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Cancer Treat Res 2007;135:185-201.
4. Kawada K, Takeo MM. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res. 2011;71:1214-1218.
5. Brown M, Assen FP, Leithner A, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science. 2018;359:1408-1411.
6. Kodama T, Mori S, Nose M. Tumor cell invasion from the marginal sinus into extranodal veins during early-stage lymph node metastasis can be a starting point for hematogenous metastasis. J Cancer Metastasis Treat. 2018;4:56.
7. Pereira ER, Kedrin D, Seano G, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science. 2018;359:1403-1407.
8. Shao L, Takeda K, Kato S, Mori S, Kodama T. Communication between lymphatic and venous systems in mice. J Immunol Methods. 2015;124:100-105.
9. Takeda T, Mori S, Kodama T. Study of fluid dynamics reveals direct communications between lymphatic vessels and venous blood vessels at lymph nodes of mice. J Immunol Methods. 2017;445:1-9.
10. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
11. Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year
follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol*. 2018;19:1385-1393.

12. Giuliani AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA*. 2011;305:569-575.

13. Kelch ID, Bogle G, Sands GB, Phillips AR, LeGrice IJ, Dunbar PR. Organ-wide 3D-imaging and topological analysis of the continuous microvascular network in a murine lymph node. *Sci Rep*. 2015;5:16534.

14. Mikada M, Sukhbaatar A, Miura Y, et al. Evaluation of the enhanced permeability and retention effect in the early stages of lymph node metastasis. *Cancer Sci*. 2017;108:846-852.

15. Leijte JA, van der Ploeg IM, Valdes Olmos RA, Nieweg OE. Strategies to enhance patient responses. *Adv Drug Deliv Rev*. 2018;130:17-38.

16. Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: enhanced permeability and retention effect in the early stages of lymph node metastasis. *Lancet*. 2003;362:527-533.

17. Shao L, Ouchi T, Sakamoto M, Mori S, Kodama T. Activation of latent metastases in the lung after resection of a metastatic lymph node in a lymph node metastasis mouse model. *Biochem Biophys Res Comm*. 2015;460:543-548.

18. Zheng J, Jia L, Mori S, Kodama T. Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes. *BMC Cancer*. 2018;18:608.

19. Ryan G, Kaminskas L, Porter C. From sewar to saviour - targeting the lymphatic system to promote drug exposure and activity. *Nat Rev Drug Discovery*. 2015;14:781-803.

20. Trevaskis N, Kaminskls L, Porter C. Nano-chemotherapeutics: maximalising lymphatic drug exposure to improve the treatment of lymphmetastatic cancers. *J Controlled Release*. 2014;193:241-256.

21. Hauley A, Davis S, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. *Adv Drug Deliv Rev*. 1995;17:129-148.

22. Khan AA, Mudasari J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanof ormulations. *Int J Nanomed*. 2013;8:2733-2744.

23. Sato T, Matsuki D, Tada A, Takeda K, Mori S. New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network. *Sci Rep*. 2016;6:32506.

24. Tada A, Horie S, Mori S, Kodama T. Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false-negative metastatic lymph nodes. *Cancer Sci*. 2017;108:2115-2121.

25. Li L, Mori S, Sakamoto M, Takahashi S, Kodama T. Mouse model of lymph node metastasis via afferent lymphatic vessels for development of imaging modalities. *PLoS ONE*. 2013;8:e55797.

26. Kodama T, Tomita N, Yagishita Y, et al. Volumetric and angiogenic evaluation of antitumor effects with acoustic liposome and high-frequency ultrasound. *Cancer Res*. 2011;71:6957-6964.

27. Kato S, Mori S, Kodama T. A novel treatment method for lymph node metastasis using a lymphatic drug delivery system with nano/microbubbles and ultrasound. *J Cancer*. 2015;6:1282-1294.

28. Shao L, Mori S, Yagishita Y, et al. Lymphatic mapping of mice with systemic lymphoproliferative disorder: usefulness as an inter-lymph node metastasis model of cancer. *J Immunol Methods*. 2013;389:69-78.

29. Aoi A, Watanabe Y, Mori S, Takahashi M, Vassaux G, Kodama T. Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound. *Ultrasound Med Biol*. 2008;34:425-434.

30. Van den Broeck W, Derore A, Simoens P. Anatomy and nomenclature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. *J Immunol Methods*. 2006;312:12-19.

31. Fujii H, Horie S, Sukhbaatar A, et al. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. *Cancer Med*. 2019;8:2241-2251. https://doi.org/10.1002/cam4.2125

How to cite this article: Fujii H, Horie S, Sukhbaatar A, et al. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. *Cancer Med*. 2019;8:2241-2251. https://doi.org/10.1002/cam4.2125